Navigation Links
Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
Date:5/16/2014

SOUTH PLAINFIELD, NJ May 16, 2014 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in % predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations. The collective data from this trial, including retrospective and subgroup analyses support the conclusion that ataluren was active and showed clinically meaningful improvements over placebo in these trials.

"The overall data from this trial are promising. Patients on ataluren experienced fewer pulmonary exacerbations and showed a stabilization in their FEV1 results, particularly in the subgroup of patients that did not use chronic inhaled aminoglycosides. Such stabilization of disease is an important clinical endpoint, particularly for this patient population that has one of the most severe forms of CF. CF patients with nonsense mutations do not produce any functional CFTR protein and therefore generally have a more severe form of cystic fibrosis. Current treatments for nonsense mutation cystic fibrosis focus on alleviating symptoms and reducing infections, whereas ataluren targets the underlying cause of disease," stated Michael Konstan, M.D., lead study investigator and Chairman of Pediatrics at from University Hospitals Rainbow Babies and & Children's Hospital in Cleveland, Ohio.

The Phase 3 double-blind, placebo-controlled study, which was conducted across 11 countries, compared ataluren (n=116) to placebo (n=116) in nmCF patients. The primary endpoint, the relative change from baseline in %-predicted FEV1 at 48 weeks, showed a positive trend favoring ataluren versus placebo, and a larger effect in patients not receiving chronic inhaled tobramycin. In the
'/>"/>

Contact: Katelyn McCarthy
katelyn.mccarthy@uhhospitals.org
216-767-8582
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
2. Celldexs Phase 1 study of CDX-1401 published in Science Translational Medicine
3. Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
4. Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer promising
5. North Shore-LIJ Completes Last Phase of $50M Upgrade of its Diagnostic Imaging Systems, $12M for GE Low-Dose CT Scanners to Reduce Patients’ Radiation Exposure
6. Stryker Hip Lawsuit News: Phase II of Mediation Set to Begin in Stryker Hip Recall Litigation Underway in New Jersey State Court, Bernstein Liebhard LLP Reports
7. LFoundry Rousset LF 110 Flash Technology Enters Industrial Phase
8. “Final Phase Fat Loss” Introduces To People An Innovative Bodyweight Training Program – Vinamy
9. CS Caregiver University Announces Its First Phase of Inductive Training for the Month of October
10. Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Novel Agents for Cancer Diagnosis and Targeted Therapy
11. For first time, drug developed based on zebrafish studies passes Phase I clinical trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MD (PRWEB) September 18, 2014 A ... shaping system has been approved by the United States Food ... available for widespread purchase in the US, landmark dermatology center ... and only practices on the east coast to use this ... only practice in the Baltimore area to offer patients the ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Members ... online with participating network dentists at UnitedConcordia.com, thanks ... dental wellness company. , "Members can book an ... 'Schedule Now' button located on the Find a ... vice president of network operations at United Concordia. ...
(Date:9/18/2014)... 2014 MD Complete , the ... a prescription, announced today that SHAPE Magazine has named ... “Best Peel” in its annual Beauty Awards. The issue ... beauty products as tested by SHAPE’s expert team. , ... results. Among the thousands of beauty products launched every ...
(Date:9/18/2014)... 2014 One Week Kitchens will have their ... Fair beginning this Saturday. Their display will be inside the ... of the products and design services that are offered at ... for fair-goers to see. This display won ‘Most Beautiful Display’ ... year and really is something to see. , The ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Each year, ... of activities that coincide with National Health IT (NHIT) ... (IT/IS) professionals. To help Norman Regional show its gratitude, ... for hospitals , is contributing giveaway items to support ... a prize drawing and offering free lunches, Norman Regional ...
Breaking Medicine News(10 mins):Health News:New FDA-Approved UltraShape Body Contouring Procedure Comes to Maryland Laser Skin and Vein 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 2Health News:United Concordia Offers Real-time Online Scheduling for their Members, Through LocalMed 3Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:One Week Kitchens Taking Display to Bloomsburg Fair 2Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2
... Technologies, Inc. (Nasdaq: EFJI ) today announced its ... revenues decreased $11.5 million, or 34%, to $22.4 million for ... for the same period in 2008. This anticipated quarterly decline ... in revenues associated with the FCC re-banding effort. "While our ...
... May 6 NeoStem, Inc. (NYSE Amex: ... and long-term storage of adult stem cells for future ... proprietary stem cell technology of Vincent C. Giampapa, ... first licensed in February 2009.The newest adult stem cell ...
... Pharmaceuticals Corp., a developer and manufacturer of medical products that ... the first quarter of 2009. , For the quarter ended ... million, or $0.06 cents per share, on revenues of $4.1 ... or $0.12 cents per share, on revenues of $5.2 million ...
... EntreMed, Inc. (Nasdaq: ENMD ), a ... cancer and inflammatory diseases, today reported financial results for ... http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) , The Company ... approximately ($3.5 million), or ($0.04) per share, compared with ...
... cancers at Women,s Dermatologic Society outreach at Family Circle ... safety and skin health, South Carolina physicians representing the ... cancer screenings and education for fans enjoying the Family ... day of outreach, local dermatologists referred 38% of the ...
... May 6 Micromet, Inc. (Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune diseases, today ... March 31, 2009.In the first quarter of 2009, Micromet ... progress in the clinic and in corporate development. ...
Cached Medicine News:Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 2Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 3Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 4Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 5Health News:EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results 6Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 2Health News:NeoStem Files Patent Application for Cosmetic Stem Cell Face Lift Technology and Expands Stem Cell Collection Network into New Jersey 3Health News:NUCRYST announces 2009 first quarter financial results 2Health News:NUCRYST announces 2009 first quarter financial results 3Health News:NUCRYST announces 2009 first quarter financial results 4Health News:NUCRYST announces 2009 first quarter financial results 5Health News:NUCRYST announces 2009 first quarter financial results 6Health News:NUCRYST announces 2009 first quarter financial results 7Health News:EntreMed Reports First Quarter 2009 Financial Results 2Health News:EntreMed Reports First Quarter 2009 Financial Results 3Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 2Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 3Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 4Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 5Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 6Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 7Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 8Health News:Micromet, Inc. Reports First Quarter 2009 Financial Results 9
(Date:9/17/2014)...   MedeAnalytics today unveils Revenue Integrity, ... visibility to a provider,s "mid-cycle" to optimize revenue ... Powered by the industry,s leading big data platform, ... between patient access and the business office where ... revenue capture, minimize audit risk and prepare providers ...
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2New Product from Vireo Systems: pH-D Feminine Health Support 2
... FRANCISCO, Calif., Aug. 25, 2011 Rigel Pharmaceuticals, Inc. ... M. Gower, chairman and chief executive officer, and Ryan ... Rigel, will present at two separate investor conferences in ... Healthcare Conference 2011Date: Thursday, September 8th at 10:20 a.m. ...
... Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), ... Chinese Medicine ("TCM") consumer products, today announced that its ... under which Nutrastar may repurchase up to US$5 million ... 12 months. Under the program, the ...
Cached Medicine Technology:Nutrastar Announces Adoption of Share Repurchase Program 2Nutrastar Announces Adoption of Share Repurchase Program 3
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
... electronic, motorized rotary microtomes ... applications of paraffin, semi-thin ... specimens in clinical, research, ... instruments display extra-ordinary ergonomic ...
... RM2235 is a robust rotary microtome ... biological specimens embedded in paraffin. The ... micrometer feed system ensures premium quality ... sectioning harder tissues. The RM2235 is ...
Medicine Products: